Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.

Join us as Senator Robinson discusses his key role in passing SB954 - which provides Pennsylvanians better access to personalized treatments following a diagnosis of cancer and other specific diseases through biomarker testing and precision medicine. Learn about Senator Robinson's journey as the bill's prime sponsor, the collaborative efforts to get it unanimously passed in the Senate and what this milestone means for patients and Pennsylvania's healthcare system.

Tune in to this episode with Representative Mullins, recipient of the 2024 State Official of the Year Award, and learn about his pivotal role in passing HB 1754 - which requires all state-regulated health plans to cover comprehensive biomarker testing. Hear about the personal motivation Representative Mullins had to be the prime sponsor of this bill, the collaborative efforts leading to this near unanimous passage in the House of Representatives and what this milestone means for patients and the Pennsylvania Healthcare system moving forward.

Ben Doranz, recipient of the 2024 Frank Baldino Bioscience CEO of the Year Award, joins Chris and Rachael this episode to discuss how he led his team through a transformative year in 2024. Under Ben's leadership, Integral Molecular secured an $8 million contract from NIAID to combat emerging viruses, as well as $2.7 million award to advance the Membrane Proteome Array for FDA qualifications as a drug development tool. If that wasn't enough, Ben also discussed the launch of Cell Surface Bio, a transformative antibody startup that will position itself as a key plater in the antibody reagent market.

Hear how his vision will transform the industry, and how he takes steps to give back to the Philadelphia and PA life sciences community.

This episode features Adrian (Ad) Rawcliffe, CEO, Adaptimmune, recipient of the Life Sciences PA 2024 Patient Impact Award.

Ad shares the story behind TECELRA - the first FDA approved engineered cell therapy for a solid tumor. Learn about the journey leading up to this groundbreaking approval, the challenges of bringing a cell therapy to market and the next steps for Adaptimmune in the landscape of tumor treatments.

This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award.

In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.

This episode features Rob Albert, CEO of B. Braun of America, the organization receiving the 2024 Patient Impact Award.

Hear from Rob and discover how B. Braun took decisive action during Hurricanes Helene and Milton to secure the supply of critical I.V. fluids to hospitals affected by these disasters. Learn how they collaborated with government agencies like the Administration for Strategic Preparedness and Response (ASPR), navigated challenges, and ensured patients had the necessary resources in a time of crisis.

Adele Oliva, recipient of the 2025 Hubert J.P. Schoemaker Leadership Award joins Chris and Rachael to discuss her impact on the life sciences industry in PA supporting the growth of commercial stage healthcare companies.

In this episode, hear how her career path ultimately led to finding a gap in the ecosystem and later found 1315 Capital. Learn about the best way to build a strong team and how she hopes the 1315 impact will live on for generations.